What treatment did your child receive for this doctor reported vision problem [PhenX]   65666-0

LOINC Code


LOINC code65666-0
nameWhat treatment did your child receive for this doctor reported vision problem [PhenX]
statusTRIAL

Fully-Specified Name

componentWhat treatment did your child receive for this doctor reported vision problem
propertyFind  =  Finding
timePt  =  Point in time:  To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements.
system^Patient
scaleNom  =  Nominal:  Nominal or categorical responses that do not have a natural ordering. (e.g., names of bacteria, reported as answers, categories of appearance that do not have a natural ordering, such as, yellow, clear, bloody.
methodPhenX

Additional Names

short nameTx child receive Dr. reported PhenX

Basic Attributes

classPHENX
type2  Clinical

Associated Observations

LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations.

Member of these Panels

62685-3PhenX - eye diseases - treatment in young children protocol 110401

History/Usage

first released
last updated2.65
last change typeMIN  - change to field other than name
change reasonUpdated the PhenX ID from "PhenX." to "PX" in Survey Question Source field to align with the variable identifier used in the PhenX Toolkit.

Related Names

Finding
Findings
Nominal
Point in time
Random
Tx
Tx child receive Dr. reported

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.

demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.